Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I, Open-Label, Multicentre Dose Escalation Study to Assess the Safety, Tolerability, and Pharmacokinetics of AZD2811 in Patients With Advanced Solid Tumours.

NCT02579226 is registered in ClinicalTrials.gov with AstraZeneca as lead sponsor.

NCT NCT02579226
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02579226 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I, Open-Label, Multicentre Dose Escalation Study to Assess the Safety, Tolerability, and Pharmacokinetics of AZD2811 in Patients With Advanced Solid Tumours.
Lead sponsor
AstraZeneca
Phase
Phase 1
Overall status
Completed
Start date
October 28, 2015
Completion date
April 3, 2020
Enrollment
72 (actual)
Sites
6

Conditions

As the registry lists them; a condition with its own page is linked.

advanced solid tumours